Clinical Trials for Metastatic Breast Cancer: What You Should Know | Dana-Farber Cancer Institute

Breast Cancer ESMO 2024 Highlights: Key Studies Discussed NATALEE, KEYNOTE 522, DESTINY-Breast12Подробнее

Emerging Experts: A Discussion With Tarantino on HER2-Low Breast Cancer and Antibody-Drug ConjugatesПодробнее

ESMO24: Nancy Lin, MD Metastatic Brain Cancer | Dana-Farber Cancer InstituteПодробнее

Behind the Breakthroughs | Closing the Gap: Equity in Clinical Trials, Research and Patient CareПодробнее

The EMBRACE Metastatic Breast Cancer Program | Dana-Farber Cancer InstituteПодробнее

What is Metastatic Breast Cancer? | Dana-Farber Cancer InstituteПодробнее

Cure X: Cancer Moonshots with Dana Farber Cancer Institute |Cure.Подробнее

Dr Waks on Ongoing Research in Residual HER2+ Breast CancerПодробнее

ESMO24: Jennifer Ligibel, MD | Dana-Farber Cancer InstituteПодробнее

KCRS24 Session Four: Ongoing Clinical Trials in Kidney Cancer/ Trials in Progress | KidneyCANПодробнее

2023 Jeffrey M. Trent Lecture in Cancer Research - Todd GolubПодробнее

Laurie H. Glimcher, MD - Oral History | Dana-Farber Cancer InstituteПодробнее

Patient Immunotherapy Summit: Breast Cancer BriefПодробнее

Prostate Cancer Conference Highlights from ASCO 2023Подробнее

How Do I Know if I Should Do Genetic Testing for Cancer Risk?Подробнее

ASCO23: Sara Tolaney, MD, MPH | Dana-Farber Cancer InstituteПодробнее

The Dana-Farber Way: Advancing Cancer Research and CareПодробнее

SABCS23: Paolo Tarantino, MD, discusses RELIEVE study | Dana-Farber Cancer InstituteПодробнее

ESMO23: Brad McGregor, MD | Dana-Farber Cancer InstituteПодробнее

Discussing Disparities in Breast Cancer Healthcare and Demand for Women of Color in Clinical TrialsПодробнее